

STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2005 **MASSACHUSETTS**

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

- TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
- TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

- TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY
- TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND
- BENEFICIARY CHARACTERISTIC
- TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT. BY TOP 10 DRUG GROUP
- TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND
- THERAPEUTIC CATEGORY
- TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
- TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY
- BENEFICIARY CHARACTERISTIC
- TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH,
- BY BENEFICIARY CHARACTERISTIC
- TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES
- AMONG NONDUALS

FOR DUAL ELIGIBLE BENEFICIARIES

- TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
- TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
- TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS. BY BRAND STATUS AND
- THERAPEUTIC CATEGORY
- TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,
- BY TOP 10 DRUG GROUP
- TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS. BY BENEFICIARY CHARACTERISTIC
- TABLE D.12, USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY
- BENEFICIARY CHARACTERISTIC
- TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

SUPPLEMENTAL TABLES

- SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES
- SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65
- SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER
- SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74
- SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84
- SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES

APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES

APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL

ELIGIBLE BENEFICIARIES

TABLE 1 OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION MASSACHUSETTS. 2005

		Eligible Beneficiaries	Number of Non-dual Eligible Beneficiaries
Inclusion Criteria (2005)	Beneficiaries (Cell)	(Cell) ^g	(Cell)
1. Beneficiaries who were eligible for Medicaid during at least one month ^a	1221761 (A)	235803 (E)	985958 (I)
2. Beneficiaries who had Medicaid pharmacy benefits during at least one month ^b	1062101 (B)	218954 (F)	843147 (J)
3. Beneficiaries who had fee-for-service pharmacy benefit coverage during at least one month ^{c, d, e}	789180 (C)	218317 (G)	570863 (K)
4. Beneficiaries who were all-year nursing facility residents ^f	31692 (D)	29169 (H)	2523 (L)

Source: Data for this table are from the MAX 2005 file for Massachusetts, released by CMS in 1/2009. This table was produced on 04/23/2009.

- a. MAX data element "Eligible Months Count" was used to determine an individual's Medicaid eligibility. All individuals who had a value greater than zero were considered as beneficiaries and counted in Cell A
- b. Counts in Cell B were obtained by excluding from Cell A beneficiaries who never had pharmacy benefit coverage during their Medicaid enrollment in 2005 (based on MAX data element "Eliqible Restricted Benefits Flac").
- c. Cell C represents the study population for Tables 2 through 7. Cell C was obtained by excluding from Cell B beneficiaries who were in managed care (MC) plans that included prescription drugs in their capitated benefit package during all months of Medicaid eligibility in 2005, because the MAX files do not include separate prescription drug claims for those beneficiaries. MC plans included health plans (PHPs), or other MC organizations that provide health care benefits under capitation arrangements. Beneficiaries included in the study population are those who were in fee-for-service or primary care case management (PCCM) programs. In addition, beneficiaries in selected states in which prescription drug benefits were not covered in the capitated benefit package in MC or PHP plans are also included (see footnote e for a list of these states). In those states, if a beneficiary spent part of the year in 6e-for-service, PCCM, or in a PHP or MC plan in which drugs were not included in the capitation, and spent part of the year in a PHP or MC plan in which drugs were capitated, only the months with fee-for-service pharmacy benefits are included in the tables. For example, if a beneficiary was in an MC plan that did not include prescription drugs in the capitation for 3 months of the year, and in a PHP with capitated drug coverage for the remaining 9 months, only the 3 months would be counted toward the number of benefit months associated with the beneficary. Therefore, benefit months included represent the benefit months with fee-for-service pharmacy benefits.
- d. The total Medicaid pharmacy reimbursement for Massachusetts in 2005 was \$1,054,271,915, of which \$38,600,412 was excluded from our analysis because those claims were made for beneficiaries who were outside the study population or took place during months that were excluded from the analysis.
- e. Enrollees in prepaid health plans (PHP) or managed care (MC) plans that did not provide a pharmacy benefit are treated as having fee-for-service pharmacy benefit coverage. There were 26 states in 2005 that had PHPs that did not include a pharmacy benefit. AL, AR, AZ, CA, CO, FL, GA, IA, KY, MA, MI, MS, NH, NV, NY, OH, OK, OR, PA, SC, SD, TN, TX, UT, WA, and WI. In addition, there were 8 states in which MC plans did not provide a pharmacy benefit (DE, IA, IL, NE, NY, TX, UT, and WV) and one state (NV) in which MC plans provided a pharmacy benefit for nonduals but not for duals. These lists were constructed from the CMS 2005 Medicaid Managed Care Enrollment Report http://www.cms.hhs.gov/MedicaidDataSourcesGenInfo/Downloads/mmcer05.pdf and by checking PHP and MC pharmacy coverage as necessary through state, PHP, and MC web sites. As a further check, we analyzed prescription drug claims for those reported as being in managed care all year in the MAX files (see Appendix Tables A.1 and A.3) to determine whether the annual number and cost of claims per person for those beneficiaries were comparable to those of beneficiaries reported as being in fee-for-service all year. If they were, that provided additional evidence that prescription drugs were not included in the managed care capitated benefit package.
- f. Cell H represents the study population for Tables D.8 through D.10D. Cell L represents the study population for Tables ND.8 through ND.10D. All-year nursing facility residents are the beneficiaries who resided in nursing facilities throughout their enrollment in 2005. These beneficiaries were identified by comparing the number of months during which the MAX files contained at least one claim from nursing facilities to the number of Medicaid eligible months. If the former is greater than or equal to the latter, the beneficiary was considered an all-year resident. If the former is less than the latter but not equal to zero, the beneficiary was considered a part-year resident. Part-year residents are treated seperately because they are likely to be short-term residents and the level and pattern of their pharmacy benefit use may differ substantially from longer-term residents. The number of part-year residents and their benefit months are presented in footnotes to Tables D.8 through D.10D and N+B18D.8 through ND.10D. Residents of mental hospitals for the aged, inpatient psychiatric facilities for individuals under age 21, or intermediate care facilities for the mentally retarded are not counted as nursing facility residents in the nursing facility testidents.
- g. Pharmacy benefit use and reimbursement among full dual eligible beneficiaries are presented in Tables D.2 through D.7D, Tables D.11 through D.13, and Supplemental Tables 1 through 11 corresponding to the sample of beneficiaries in Cell G. To determine Medicaid-Medicare dual eligibility status, two MAX data elements ("Eligibile Medicare Crossover Code -- Annual New Values" and "Eligible Restricted Benefits Flag") were used in combination. The dual eligibile tables include all dual eligible benefit months in which the beneficiary had a fee-for-service pharmacy benefit.

Beneficiaries represented in Cell G, the dual study population, include all dual eligible beneficiaries who had a fee-for-service pharmacy benefit at least during one month in 2005. The dual eligible tables include all dual eligible benefit months in which the beneficiary had a fee-for-service pharmacy benefit.

Characteristics of non-dual eligible beneficiaries represented by Cell J are shown in Appendix Table A.1 and characteristics of non-dual eligible beneficiaries and their benefit months included in Cell J but excluded from Cell K are shown in Appendix Table A.2. Characteristics of dual eligible beneficiaries represented by Cell F are shown in Appendix Table A.3, and characteristics of dual eligible beneficiaries and their benefit months included in Cell F but excluded from Cell G are shown in Appendix Table A.4.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; HMO = health maintenance organization; MAX = Medicaid Analytic Extract; MC = managed care; PCCM = primary care case management; PHP = prepaid health plan.

TABLE 2

CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY^{A, b}

MASSACHUSETTS, 2005

		N	umber of E		SSACHUSE es	:113, 2005		N	umber of Be	nefit Months	Adults Children Unknown 1,102,289 2,091,654 0 616,313 0 0 977,014 0 79,536 498,222 0 827,016 94 0 195,634 11 0 103 0 0 0 0 0					
Beneficiary						Other/						Other/				
Characteristics	All	Aged	Disabled	Adults	Children	Unknown	All	Aged	Disabled	Adults	Children	Unknown				
All	789,180	126,522	219,524	155,682	287,452	0	6,910,199	1,331,100	2,385,156	1,102,289	2,091,654	0				
Age																
5 and younger	102,740	2	3,523	0	99,215	0	649,994	24	33,657	0	616,313	0				
6-14	135,258	2	11,497	0	123,759	0	1,102,911	17	125,880	0	977,014	0				
15-20	86,757	1	10,879	11,425	64,452	0	693,772	12	116,002	79,536	498,222	0				
21-44	197,321	6	78,383	118,911	21	0	1,679,250	61	852,079	827,016	94	0				
45-64	140,579	6	115,242	25,326	5	0	1,453,239	56	1,257,538	195,634	11	0				
65-74	49,833	49,813	0	20	0	0	546,515	546,412	0	103	0	0				
75-84	42,055	42,055	0	0	0	0	449,228	449,228	0	0	0	0				
85 and older	34,635	34,635	0	0	0	0	335,285	335,285	0	0	0	0				
Unknown	2	2	0	0	0	0	5	5	0	0	0	0				
Gender																
Female	458,312	90,175	110,972	115,229	141,936	0	4,022,555	952,888	1,215,289	823,480	1,030,898	0				
Male	330,868	36,347	108,552	40,453	145,516	0	2,887,644	378,212	1,169,867	278,809	1,060,756	0				
Unknown	0	0	0	0	0	0	0	0	0	0	0	0				
Race																
White	384,255	82,465	148,236	58,166	95,388	0	3,707,752	887,250	1,642,601	429,779	748,122	0				
African American	67,739	6,494	16,795	14,649	29,801	0	556,812	71,680	183,000	97,119	205,013	0				
Other/unknown	337,186	37,563	54,493	82,867	162,263	0	2,645,635	372,170	559,555	575,391	1,138,519	0				
Use of Nursing Facilities ^c																
Entire year	31,692	28,404	3,280	3	5	0	317,949	281,447	36,418	26	58	0				
Part year	19,567	14,458	4,916	132	61	0	190,548	135,885	52,965	1,202	496	0				
None	737,921	83,660	211,328	155,547	287,386	0	6,401,702	913,768	2,295,773	1,101,061	2,091,100	0				
Maintenance Assistance Status	5															
Cash	244,693	52,822	127,736	27,680	36,455	0	2,470,957	603,751	1,431,911	179,005	256,290	0				
Medically needy	22,145	13,985	8,160	0	0	0	226,070	140,249	85,821	0	0	0				
Poverty-related	328,585	34,465	64,200	0	229,920	0	2,682,878	350,923	669,183	0	1,662,772	0				
Other/unknown	193,757	25,250	19,428	128,002	21,077	0	1,530,294	236,177	198,241	923,284	172,592	0				
Dual Medicare Status ^d																
Full dual, all year	216,214	111,154	103,527	1,529	4	0	2,344,153	1,172,085	1,158,402	13,634	32	0				
Full dual, part year	2,103	2,037	66	0	0	0	23,326	22,580	746	0	0	0				
Non-dual, all year	570,863	13,331	115,931	154,153	287,448	0	4,542,720	136,435	1,226,008	1,088,655	2,091,622	0				
Managed Care (MC) Status																
Fee-for-service (FFS) all year	611,176	126,179	207,973	96,705	180,319	0	6,192,839	1,329,069	2,319,011	873,782	1,670,977	0				
FFS part year, with Rx claims	75,480	299	8,450	28,321	38,410	0	405,106	1,821	54,458	142,936	205,891	0				
FFS part year, no Rx claims					68,723	0	312,254	210	11,687	85,571	214,786	0				

a. Table 2 includes the beneficiaries represented by Cell C of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

d. The "Full dual, all year" group includes beneficiaries who had Medicare coverage as well as Medicaid fee-for-service pharmacy benefits during all months of Medicaid enrollment in 2005. The "Full dual, part year" group includes beneficiaries who had such benefits for some, but not all, months of their enrollment. The "Non-dual, all year" group includes beneficiaries who were never dually eligible. Refer to footnote g of Table 1 for more information about how we determined dual eligibility status.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

Beneficiary Characteristics	Percentage with at Least One Rx	Mean Number of Rx	Mean Rx \$	\$ per Rx	Mean \$, All Medicaid FFS \$c	Rx \$ as a Percentage of All Medicaid FFS \$ ^d	Number of Beneficiaries
All	65.5	19.1	\$1,287	\$67	\$8,626	14.9	789,180
Age			, , -	•	,		
5 and younger	45.1	2.1	85	40	3,695	2.3	102,740
6-14	47.4	4.1	296	72	2,919	10.1	135,258
15-20	51.9	5.4	521	97	4,167	12.5	86,757
21-44	68.2	15.9	1,299	82	7,655	17.0	197,321
45-64	83.3	38.4	2,861	75	13,095	21.8	140,579
65-74	83.9	37.7	2,150	57	10,805	19.9	49,833
75-84	87.0	43.6	2,176	50	18,205	12.0	42,055
85 and older	89.4	45.3	1,863	41	29,343	6.3	34,635
Unknown	100.0	17.0	616	36	9,328	6.6	2
Basis of Eligibilitye							
Aged	86.4	41.8	2,080	50	18,340	11.3	126,522
Disabled	85.0	36.0	2,975	83	14,887	20.0	219,524
Adults	58.2	6.9	341	50	2,812	12.1	155,682
Children	45.2	2.8	161	57	2,718	5.9	287,452
Unknown	0.0	0.0	0	0	0	0.0	0
Gender							
Female	68.8	21.2	1,277	60	8,835	14.5	458,312
Male	60.8	16.2	1,301	80	8,338	15.6	330,868
Unknown	0.0	0.0	0	0	0	0.0	0
Race							
White	74.9	26.3	1,769	67	11,496	15.4	384,255
African American	55.9	12.4	886	71	6,483	13.7	67,739
Other/unknown	56.7	12.2	818	67	5,787	14.1	337,186
Use of Nursing Facil	ities ^f						
Entire year	94.1	64.3	3,058	48	50,918	6.0	31,692
Part year	94.9	53.9	2,900	54	33,195	8.7	19,567
None	63.4	16.2	1,168	72	6,158	19.0	737,921
Maintenance Assista	ance Status						
Cash	76.9	27.6	1,961	71	10,575	18.5	244,693
Medically needy	81.0	34.8	1,991	57	18,730	10.6	22,145
Poverty related	57.4	14.4	978	68	7,362	13.3	328,585
Other/unknown	62.9	14.4	880	61	7,155	12.3	193,757

a. Table 3 includes beneficiaries represented by Cell C of Table 1.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE 4 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC $^{a,\,b}$ MASSACHUSETTS, 2005

						nber of Rx, F		Number				
Beneficiary Characteristics	Mean Number of Rx	Mean Rx \$	Rx \$ as a Percentage of All Medicaid FFS \$ ^c	None	More than 0, but 1 or Less	More than 1, but 2 or Less		More than 5, but 10 or Less	More than 10	Mean \$, All Medicaid FFS \$ ^d	Beneficiaries	Benefit Months
All	2.2	\$147	14.9	34.5	32.0	8.6	14.4	8.5	2.0	\$985	789,180	6,910,199
Age												
5 and younger	0.3	14	2.3	54.9	41.0	2.7	1.3	0.1	0.0	584	102,740	649,994
6-14	0.5	36	10.1	52.6	38.8	4.5	3.5	0.5	0.0	358	135,258	1,102,911
15-20	0.7	65	12.5	48.1	40.0	6.0	4.7	1.0	0.1	521	86,757	693,772
21-44	1.9	153	17.0	31.8	36.4	10.7	14.2	5.8	1.1	900	197,321	1,679,250
45-64	3.7	277	21.8	16.7	20.9	12.2	27.5	18.2	4.5	1,267	140,579	1,453,239
65-74	3.4	196	19.9	16.1	21.7	13.2	26.9	17.7	4.4	985	49,833	546,515
75-84	4.1	204	12.0	13.0	16.3	11.9	29.5	23.1	6.2	1,704	42,055	449,228
85 and older	4.7	192	6.3	10.6	11.8	10.7	31.2	29.1	6.7	3,031	34,635	335,285
Unknown	6.8	246	6.6	0.0	0.0	0.0	50.0	50.0	0.0	3,731	2	5
Basis of Eligibility	е											
Aged	4.0	198	11.3	13.6	17.2	12.1	28.9	22.6	5.6	1,743	126,522	1,331,100
Disabled	3.3	274	20.0	15.0	25.1	13.0	27.1	16.1	3.8	1,370	219,524	2,385,156
Adults	1.0	48	12.1	41.8	40.1	8.7	7.5	1.7	0.2	397	155,682	1,102,289
Children	0.4	22	5.9	54.8	39.4	3.5	2.1	0.3	0.0	374	287,452	2,091,654
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Gender												
Female	2.4	146	14.5	31.2	32.0	9.0	15.6	9.8	2.4	1,007	458,312	4,022,555
Male	1.9	149	15.6	39.2	31.9	7.9	12.7	6.8	1.5	955	330,868	2,887,644
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Race												
White	2.7	183	15.4	25.1	30.0	10.6	19.4	12.1	2.9	1,191	384,255	3,707,752
African American	1.5	108	13.7	44.1	33.3	6.9	10.1	4.7	0.9	789	67,739	556,812
Other/unknown	1.6	104	14.1	43.3	34.0	6.6	9.6	5.3	1.2	738	337,186	2,645,635
Use of Nursing Fa	cilities ^f											
Entire year	6.4	305	6.0	5.9	6.0	7.1	27.7	38.3	15.0	5,075	31,692	317,949
Part year	5.5	298	8.7	5.1	10.0	9.7	32.5	33.0	9.7	3,409	19,567	190,548
None	1.9	135	19.0	36.6	33.7	8.6	13.3	6.6	1.2	710	737,921	6,401,702
Maintenance Assis	stance Status	3										
Cash	2.7	194	18.5	23.1	29.5	11.6	21.4	11.9	2.5	1,047	244,693	2,470,957
Medically needy	3.4	195	10.6	19.0	21.3	11.9	25.7	17.9	4.2	1,835	22,145	226,070
Poverty related	1.8	120	13.3	42.6	32.9	6.1	10.2	6.5	1.6	902	328,585	2,682,878
Other/unknown	1.8	111	12.3	37.1	34.7	8.5	11.3	6.6	1.7	906	193,757	1,530,294

a. Table 4 includes the beneficiaries represented by Cell C of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

- e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE 5 AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC $^{a, b, c}$ MASSACHUSETTS, 2005

				Patente		d-Name	Off-Pater	nt Bran	d-Name						
		All Rx			Drugs			Drugs		Gen	of Rx Rx \$ \$ per R 1.4 \$30 \$3				
Beneficiary Characteristics	Number of Rx	Rx\$	\$ per Rx	Number of Rx	Rx\$	\$ per Rx	Number of Rx	Rx\$	\$ per Rx	Number of Rx	Rx\$	\$ per Rx			
All	2.2	\$147	\$67	0.8	\$113	\$146	0.0	\$4	\$101	1.4	\$30	\$22			
Age															
5 and younger	0.3	14	40	0.1	10	107	0.0	0	54	0.2	3	12			
6-14	0.5	36	72	0.2	31	128	0.0	1	101	0.3	5	18			
15-20	0.7	65	97	0.3	55	195	0.0	2	98	0.4	8	22			
21-44	1.9	153	82	0.6	117	185	0.0	4	113	1.2	31	26			
45-64	3.7	277	75	1.3	209	163	0.1	7	129	2.4	61	26			
65-74	3.4	196	57	1.3	151	120	0.0	4	92	2.1	41	19			
75-84	4.1	204	50	1.5	156	104	0.1	4	62	2.5	43	17			
85 and older	4.7	192	41	1.6	143	89	0.1	5	54	3.0	44	15			
Unknown	6.8	246	36	3.4	220	65	0.2	5	25	3.2	21	7			
Basis of Eligibility	d														
Aged	4.0	198	50	1.4	151	106	0.1	4	67	2.5	43	17			
Disabled	3.3	274	83	1.2	212	179	0.1	7	129	2.1	55	27			
Adults	1.0	48	50	0.3	33	119	0.0	2	83	0.7	13	20			
Children	0.4	22	57	0.2	18	114	0.0	1	83	0.2	4	17			
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0			
Gender															
Female	2.4	146	60	0.8	110	131	0.0	4	92	1.5	32	21			
Male	1.9	149	80	0.7	117	171	0.0	3	122	1.1	29	25			
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0			
Race															
White	2.7	183	67	1.0	140	144	0.0	5	102	1.7	39	23			
African American	1.5	108	71	0.5	85	164	0.0	2	105	1.0	20	21			
Other/unknown	1.6	104	67	0.6	81	145	0.0	3	98	1.0	21	21			
Use of Nursing Fa	cilities ^e														
Entire year	6.4	305	48	2.2	230	102	0.1	8	55	4.0	67	17			
Part year	5.5	298	54	1.9	225	117	0.1	7	74	3.5	65	19			
None	1.9	135	72	0.7	104	155	0.0	3	115	1.2	28	24			
Maintenance Assi	stance Sta	tus													
Cash	2.7	194	71	1.0	150	155	0.0	5	113	1.7	40	23			
Medically needy	3.4	195	57	1.3	149	118	0.1	5	86	2.1	41	20			
Poverty related	1.8	120	68	0.6	92	145	0.0	3	102	1.1	25	23			
Other/unknown	1.8	111	61	0.6	85	134	0.0	3	84	1.2	24	20			

other than the original patent holder. In Massachusetts, 0.3 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions

a. Table 5 includes the beneficiaries represented by Cell C of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies

ad778d7b6615 (October 26, 2007)

- d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE 6 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY $^{a,\ b,\ c,\ d}$ MASSACHUSETTS, 2005

		Number of Rx per Benefit \$ per Benefit Month Among Month Among Users Users \$ per Rx					- -	Users ^e									
Therapeutic Category	P Total	atented Brand- Name		Seneric			Off- Patent Brand- Name G	Seneric	F Total	Patented Brand- Name	Off- Patent Brand- Name (Total Number of Rx	Total Rx \$	Number of Users	As a Percentage of All Benes	Number of Benefit Months
Anti-infective Agents	0.3	0.1	0.0	0.2	\$32	\$26	\$2	\$4	\$111	\$305	\$76	\$23	894,085	\$98,982,448	287,895	36.5	3,063,901
Biologicals	0.2	0.1	0.0	0.0	92	48	23	21	579	398	3,600	659	5,920	3,428,695	3,462	0.4	37,254
Antineoplastic Agents	0.5	0.2	0.0	0.4	133	108	1	24	260	681	616	68	49,531	12,886,348	9,141	1.2	97,056
Endocrine/Metabolic Drugs	0.7	0.3	0.0	0.5	35	25	2	8	48	101	73	17	1,428,870	68,524,550	180,986	22.9	1,932,240
Cardiovascular Agents	1.4	0.4	0.0	1.0	48	34	0	13	35	83	50	14	3,095,746	107,149,401	204,553	25.9	2,246,933
Respiratory Agents	0.5	0.3	0.0	0.2	35	33	0	2	66	99	55	10	873,669	57,513,049	151,524	19.2	1,629,023
Gastrointestinal Agents	0.6	0.4	0.0	0.2	50	46	0	4	83	126	46	17	1,016,060	84,153,635	152,305	19.3	1,670,201
Genitourinary Agents	0.4	0.2	0.0	0.1	24	20	1	3	65	89	55	26	191,182	12,504,956	47,963	6.1	522,178
CNS Drugs	1.2	0.4	0.0	0.8	109	86	0	23	87	193	78	29	3,121,961	273,087,676	230,839	29.3	2,511,479
Stimulants/Anti-obesity/Anorexia	0.6	0.5	0.0	0.2	55	48	0	8	86	104	102	41	193,183	16,558,415	28,386	3.6	299,157
Miscellaneous Psychological/ Neurological Agents	0.8	0.8	0.0	0.0	145	145	0	0	188	190	0	17	139,501	26,285,988	17,177	2.2	181,232
Analgesics and Anesthetics	0.6	0.1	0.0	0.5	30	11	3	16	50	156	238	31	1,441,692	72,629,410	225,272	28.5	2,426,104
Neuromuscular Agents	8.0	0.3	0.0	0.5	64	47	2	16	76	152	100	30	1,190,577	90,100,000	126,405	16.0	1,401,829
Nutritional Products	0.4	0.0	0.0	0.3	6	1	0	5	16	44	15	15	222,897	3,672,918	59,807	7.6	599,027
Hematological Agents	8.0	0.2	0.0	0.6	90	83	0	7	118	450	68	12	409,990	48,541,483	49,570	6.3	537,744
Topical Products	0.3	0.1	0.0	0.2	14	9	0	4	41	78	45	20	713,852	28,928,996	195,191	24.7	2,102,338
Miscellaneous Products	0.3	0.2	0.0	0.1	62	47	5	11	205	271	294	93	48,976	10,050,002	15,049	1.9	161,385
Unknown Therapeutic Category	0.3	0.0	0.0	0.0	7	0	0	0	25	0	0	0	27,155	673,533	8,505	1.1	94,928
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	15,064,847	1,015,671,503	n.a.	n.a.	n.a.

the original patent holder. In Massachusetts, 0.3 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table 6 includes the beneficiaries represented by Cell C of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than

TABLE 7 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP $^{a,\ b,\ c}$ MASSACHUSETTS, 2005

	_		Users		Am	nong User	'S
Top 10 Drug Groups	Total Medicaid Rx	Number	As a Percentage of All Beneficiaries	Number of Benefit Months	Number of Rx per Benefit Month	\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$193,111,942	131,634	16.7	1,476,988	0.7	\$190	\$131
ANTICONVULSANT	79,817,661	108,211	13.7	1,217,981	0.7	89	66
ULCER DRUGS	70,988,795	139,462	17.7	1,549,644	0.5	92	46
ANTIVIRAL	69,539,269	27,459	3.5	307,654	0.5	471	226
ANTIDEPRESSANTS	67,515,581	237,673	30.1	2,630,156	0.6	46	26
ANTIHYPERLIPIDEMIC	57,820,691	101,581	12.9	1,150,699	0.6	87	50
ANTIASTHMATIC	45,236,860	179,461	22.7	1,962,588	0.3	69	23
ANALGESICS - Narcotic	45,226,671	224,271	28.4	2,465,579	0.4	51	18
ANTIDIABETIC	39,719,306	98,527	12.5	1,100,693	0.6	57	36
MISC. HEMATOLOGICAL	29,325,959	14,260	1.8	156,709	0.6	324	187
Total	698,302,735	1,262,539		14,018,691	n.a.	n.a.	n.a.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table 7 includes the beneficiaries represented by Cell C of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).